Open Access Research Article
White Black Legal – International Law Journal · ISSN 2581-8503
INTELLECTUAL PROPERTY RIGHTS AND REGULATORY GAPS IN THE INDIAN COSMECEUTICAL INDUSTRY
Read the Full Research Paper
Access the complete open-access article in PDF format. No login is required.
Abstract
INTELLECTUAL PROPERTY RIGHTS AND REGULATORY
GAPS IN THE INDIAN COSMECEUTICAL INDUSTRY
AUTHORED
BY - A.AARTHI & A.BENTLEY BENEDICT MARAN
ABSTRACT
Cosmeceuticals occupy an increasingly
important space between cosmetics and pharmaceuticals. Their formulations may
contain bioactive ingredients and their marketing may make claims concerning
skin structure, appearance or function, yet Indian law does not expressly
recognise “cosmeceutical” as a separate regulatory category. This paper
examines the resulting interaction between product classification, intellectual
property protection and consumer protection. It analyses the Drugs and
Cosmetics Act, 1940, the Patents Act, 1970 and the Consumer Protection Act,
2019, with particular attention to the cosmetic–drug boundary, patentability of
formulations, misleading claims and the practical limitations of trade-secret
protection. It also compares the Indian position with the claims-based approach
of the United States and the more structured safety and substantiation model of
the European Union. The analysis finds a regulatory mismatch: products with
therapeutic-adjacent claims may enter the market through a cosmetics pathway
while innovators may encounter demanding patentability standards, particularly
where formulations combine known ingredients. The paper argues for a
proportionate hybrid framework that distinguishes ordinary cosmetics,
cosmeceuticals and drugs; requires evidence proportionate to the claim and
risk; strengthens controls over misleading representations; and aligns
intellectual-property incentives with regulatory expectations. The proposed
reforms are intended to improve legal certainty, consumer information,
innovation incentives and regulatory consistency without treating all
cosmeceuticals as pharmaceutical products.[1]
Keywords: Cosmeceuticals; Intellectual Property; Patent Law;
Trademark Law; Consumer Protection; Regulatory Classification; Section 3(d);
Drugs and Cosmetics Act; Misleading Claims; Claim Substantiation.
1. INTRODUCTION
1.1
Concept and Significance
The term “cosmeceutical” combines “cosmetic”
and “pharmaceutical” and is generally used for products positioned between
conventional personal-care products and therapeutic products. The category
includes formulations containing bioactive ingredients such as peptides,
retinoids,
hydroxy acids, botanical extracts and other
actives that are marketed as providing benefits beyond cleansing or basic
beautification. The supplied study notes the rapid growth of the global market
and the increasing consumer demand for evidence-based skincare.[2]
The legal significance of the category lies less in the label “cosmeceutical”
than in the relationship between formulation, intended use and marketing
claims. A product may look and be sold like a cosmetic while making
representations about physiological effects. This creates a boundary problem
because regulation, intellectual property and consumer protection may apply
different thresholds to the same product. The result is uncertainty for
manufacturers and consumers and a risk that regulatory treatment does not
correspond to the strength of the claim being made.
1.2
The Cosmetic–Drug Boundary in India
The Drugs and Cosmetics Act, 1940 (“DCA”)
uses separate definitions for “cosmetic” and “drug”. The definition of cosmetic
is directed to preparations applied to the human body for cleansing,
beautifying, promoting attractiveness or altering appearance, whereas the
definition of drug covers products intended for the diagnosis, treatment,
mitigation or prevention of disease and substances affecting bodily functions
or conditions.² This binary structure does not expressly identify a middle
category for products that make therapeutic-adjacent claims without claiming to
diagnose or treat disease.[3]
The practical difficulty is illustrated by
claims such as “reduces the appearance of wrinkles”, “improves skin
elasticity”, “stimulates collagen” or “repairs sun-damaged skin”. The legal
character of such statements depends on how the claim is understood and
applied. Claims limited to cleansing, moisturising or beautifying are more
readily accommodated within the cosmetic category, while disease-treatment
claims move towards drug regulation. Guidance and regulatory practice therefore
become important in deciding where a particular claim falls.
1.3
Intellectual Property and Consumer-Protection Implications
Regulatory ambiguity has direct
intellectual-property consequences. A formulation made from known ingredients
may encounter the exclusions relating to mere admixture and new properties or
uses of known substances under the Patents Act, 1970.⁴ At the same time, a
brand may seek trademark protection for a distinctive product name while using
the packaging and advertising surrounding that mark to communicate health or
efficacy benefits. Trademark registration and advertising legality are
therefore related but distinct questions. Consumer-protection law supplies an
additional layer of control over false or misleading representations.[4]
The central proposition of this paper is that
the problem is systemic rather than confined to one statute. A product may face
relatively modest cosmetic requirements at market-entry stage, demanding
patentability requirements when protection is sought, and a fragmented
enforcement environment when claims are challenged. The resulting misalignment
can reduce incentives for evidence-based innovation while increasing the
possibility of consumer confusion.
2. RESEARCH PROBLEM, OBJECTIVES AND
METHODOLOGY
2.1
Statement of the Problem
Indian law does not expressly define or
classify cosmeceuticals as a distinct category. The existing binary
cosmetic–drug structure is therefore required to accommodate products with
hybrid characteristics. This produces four connected problems: first, uncertainty
over classification and permissible claims; second, difficulty in securing
appropriate patent protection for formulations that combine known actives;
third, potential consumer deception through health-oriented branding and
advertising; and fourth, a gap between the level of evidence suggested by a
claim and the regulatory evidence expected of the product.
The problem is not simply that regulation is
“strict” or “lenient”. Rather, the thresholds operate unevenly. A manufacturer
may be able to market a product with a cosmetic classification while an
inventor seeking a patent may face a demanding showing concerning novelty,
inventive step, or the effect of a claimed combination. This can encourage
reliance on secrecy and branding rather than disclosure and formal protection,
while leaving consumers without a consistent means of evaluating claims.
2.2
Objectives and Research Questions
The study has five principal objectives:
(i)
to
examine the Indian classification of cosmetics and drugs and its application to
cosmeceuticals;
(ii)
to
analyse patentability barriers under the Patents Act, particularly sections
3(d), 3(e) and 2(ja);
(iii)
to
evaluate trademark and consumer-protection responses to misleading health and
efficacy claims;
(iv)
to
compare the Indian position with the United States and European Union; and
(v)
to
propose reforms capable of aligning innovation incentives with safety and
consumer protection.
The principal research questions are whether
Indian law requires a distinct regulatory category for cosmeceuticals; whether
existing patentability standards appropriately accommodate formulation
innovation; whether current controls adequately address health and efficacy
claims; and what features of foreign regulatory systems can be adapted to
Indian conditions. The working hypothesis is that the absence of a dedicated
category, combined with restrictive or uncertain intellectual-property
pathways, produces a regulatory gap that weakens both innovation incentives and
consumer protection.
2.3
Methodology and Scope
The research follows a doctrinal and
comparative legal method. It examines the relevant Indian statutes and rules,
regulatory guidance, judicial authority identified in the supplied material,
patent-office guidance and selected international frameworks. The comparative
component focuses on the United States and European Union because they
demonstrate two different methods of dealing with the cosmetic–drug boundary:
claims-based classification and enhanced regulation within the cosmetics
framework. The study is limited to legal and regulatory analysis and does not
attempt an economic or epidemiological assessment of the market.
3. INDIAN REGULATORY FRAMEWORK FOR
COSMECEUTICALS
3.1
Statutory Definitions and Classification
The DCA is the starting point for determining
whether a product is regulated as a cosmetic or drug. Its definitions were
designed around a distinction between products concerned with cleansing or
appearance and products concerned with disease, treatment or bodily function.
For cosmeceuticals, however, the intended use may be communicated through
claims that fall between these poles. The absence of an express statutory
definition means that the legal status of the product must be inferred from the
existing categories rather than determined under a dedicated framework.[5]
Regulatory guidance consequently assumes
importance. The supplied material describes a claims-oriented approach in which
structure-function or aesthetic statements are more compatible with cosmetic
treatment, whereas disease-related or therapeutic claims can bring the product
within drug regulation. The distinction is difficult where the wording is
subtle. “Reduces the appearance of fine lines” communicates an aesthetic
outcome, while “reduces wrinkles” may suggest a direct physiological effect.
Such linguistic distinctions can have regulatory consequences without
necessarily corresponding to a meaningful difference in the consumer’s
perception of the product.
3.2 Safety, Efficacy and Enforcement Gaps
The paper identifies a further gap between
the evidentiary expectations applicable to drugs and those applicable to
cosmetics. Cosmetics do not generally enter the market through the same
clinical-development pathway as pharmaceutical products. Consequently, a
product marketed with strong efficacy language may be supported by a different
level of evidence from that expected of a drug making a comparable
physiological claim. The issue is not that every cosmetic claim requires a
pharmaceutical clinical trial; rather, the evidence should be proportionate to
the nature and risk of the claim.[6]
The enforcement structure also contributes to uncertainty. The DCA operates
through central and state regulatory institutions, and differences in
interpretation or enforcement can create practical compliance variation. A
manufacturer seeking nationwide consistency may therefore modify claims, labels
or supporting material to manage different regulatory expectations. Such
fragmentation increases compliance costs and can produce inconsistent outcomes
for products that are substantively similar.
4. PATENTABILITY OF COSMECEUTICAL
INNOVATIONS
4.1
General Patentability Standards
Cosmeceutical inventions are assessed under
the general patent framework unless a statutory exclusion applies. The Patents
Act, 1970 requires an invention to satisfy the statutory requirements of
invention, novelty and inventive step and to be capable of industrial
application. Section 2(ja) defines inventive step in terms of technical
advancement or economic significance, or both, together with non-obviousness to
a person skilled in the art. Thus, the fact that a formulation is commercially
successful or cosmetically attractive does not by itself establish
patentability.
4.2
Section 3(e): Mere Admixture
Section 3(e) excludes a substance obtained by
mere admixture where the resulting substance does not exhibit properties
fundamentally different from those of the constituents. This provision is
particularly relevant to cosmeceuticals because many formulations combine known
ingredients such as vitamins, botanical extracts, peptides, antioxidants or
retinoids in different concentrations. A claim that merely places familiar
ingredients together, without demonstrating a meaningful technical result, may
therefore encounter an exclusion even where the final product is commercially
new.[7]
For formulation applicants, the important
question is consequently not whether every ingredient is individually known,
but whether the combination produces a legally relevant result that
distinguishes it from a simple aggregation of known properties. Evidence of
unexpected stability, compatibility, delivery characteristics or another
demonstrable technical effect may strengthen the case for patentability. The
supplied paper refers to Indian Patent Office guidance as relevant to the
examination of cosmetic and pharmaceutical formulations.[8]
4.3
Section 3(d) and the Significantly Enhanced Effect
Section 3(d) addresses, among other things,
the discovery of a new property or new use of a known substance unless the
statutory requirement concerning a significantly enhanced effect is satisfied.
The provision has particular importance where an applicant relies on a known
active ingredient but claims a new formulation, combination or result. The
Supreme Court’s decision in Novartis AG v Union of India provides the leading
authority on the operation of section 3(d) and emphasises the need for evidence
directed to the statutory standard rather than a merely formal change to a
known substance.[9]
The difficulty for cosmeceuticals is one of
proportionality. Pharmaceutical patent cases may involve therapeutic efficacy
as the relevant outcome, whereas cosmetic innovation may concern measurable
changes in skin appearance, texture, elasticity, stability or delivery.
Treating every cosmeceutical innovation as if it must demonstrate
pharmaceutical therapeutic efficacy risks making the patent threshold
disconnected from the technical contribution actually claimed. At the same
time, lowering the standard so far that any new combination of known
ingredients becomes patentable would weaken the inventive-step and
anti-evergreening functions of patent law.
4.4
Illustrative Formulation Analysis
Consider an anti-ageing serum containing
encapsulated retinol, a peptide complex, green-tea extract, vitamin C and
hyaluronic acid, supported by stability studies, in-vitro evidence and consumer
testing. The existence of separate prior art for each component would not
automatically answer the patent question. The analysis should consider the
claimed formulation as a whole, the prior art, the technical problem addressed,
the skilled person’s expectations and whether the claimed combination produces
an unexpected or otherwise patent-relevant result.
If the evidence demonstrates only that each
known ingredient performs its established function, an objection based on
obviousness or mere admixture may be persuasive. If, however, the particular
combination or delivery system produces an unexpected technical effect such as
a demonstrable improvement in stability or controlled delivery the applicant
may have a stronger basis for patent protection. The key reform need is
therefore not a cosmetic-specific monopoly, but clearer and proportionate
examination criteria for cosmetic formulation technologies.
5. TRADEMARKS, ADVERTISING AND CONSUMER
PROTECTION
5.1
Trademark Protection and Health-Suggestive Branding
Trademark protection serves a different
function from patent protection. It protects source-identifying signs rather
than the underlying formulation. The Trade Marks Act, 1999 contains absolute
grounds of refusal, including circumstances involving lack of distinctiveness,
descriptiveness and certain misleading indications. A mark suggesting efficacy
may therefore raise issues of distinctiveness and deception, but registration
of a mark does not amount to scientific certification of the claims communicated
by the product as a whole.[10]
The distinction is important for
cosmeceuticals because brand names, taglines, packaging and promotional
material frequently work together. Terms such as “clinically proven”,
“dermatologist approved”, “pharmaceutical grade” or “collagen boosting” may communicate
a level of efficacy, testing or regulatory oversight that the product does not
actually possess. The legal analysis should therefore separate the
registrability of the mark from the truthfulness and substantiation of the
associated representation.
5.2
Misleading Claims and the Consumer Protection Act
The Consumer Protection Act, 2019 treats
false or misleading representations as an unfair trade practice. This provides an important consumer-facing
remedy, but enforcement can be difficult where technical evidence is required
to establish whether a claim is scientifically justified. A consumer may
understand “clinically proven” to mean that a robust clinical study exists,
while the manufacturer may rely on a small consumer-perception survey or
laboratory testing. The resulting information asymmetry makes substantiation
standards particularly important.[11]
The case law identified in the supplied
paper, including Colgate-Palmolive Co v Hindustan Lever Ltd, illustrates the
broader judicial concern with advertising representations and consumer
perception. For cosmeceuticals, the principle supports a stronger requirement
that claims be proportionate to the evidence behind them. An aesthetic claim
supported by an appropriate consumer study should not be presented as though it
were proof of a therapeutic effect.[12]
5.3
The Advertising Standards Gap
The principal weakness is fragmentation. Drug
regulation, cosmetic regulation, trademark law and consumer protection may
address different parts of the same representation, but they do not necessarily
operate through a single claim-substantiation system. A manufacturer can
therefore face uncertainty about what evidence must be generated before a claim
is placed on packaging or in advertising. A dedicated cosmeceutical framework
should close this gap by linking categories of claims to minimum evidentiary
requirements.
6. TRADE SECRETS AND INNOVATION STRATEGY
Where patent protection is uncertain,
manufacturers may prefer confidentiality. Formulations, manufacturing
parameters, stability data and process know-how can have commercial value if
they are kept secret. The supplied research identifies secrecy as a practical
alternative to patent disclosure, but also highlights a central weakness: a
formulation contained in a marketable consumer product may be capable of
analytical examination and reverse engineering.[13]
Trade-secret protection is therefore not a
substitute for a patent in every circumstance. A patent can provide an
enforceable exclusionary right for a defined term in return for disclosure. A
trade secret may last longer, but only while secrecy is maintained and does not
necessarily prevent independent discovery or legitimate reverse engineering.
For cosmeceutical companies, the appropriate strategy may therefore be to
patent aspects that are difficult to keep secret while protecting manufacturing
know-how, supplier information and process parameters through confidentiality
measures.
The Indian framework should strengthen
contractual and procedural protection for confidential information rather than
create an automatic monopoly over undisclosed formulations. The reform
objective should be to reduce misappropriation while preserving legitimate
competition and independent discovery.
7.1
United States
The United States provides a useful contrast
because the Food and Drug Administration uses intended use and claims as
central elements in distinguishing cosmetics from drugs. Products making
disease-treatment or comparable therapeutic claims can fall within drug
regulation even when they are presented in a cosmetic form. Products confined
to cosmetic purposes remain within the cosmetics framework. This approach
places substantial responsibility on the wording and context of the claim and
can provide stronger protection against the use of cosmetic presentation to
avoid drug regulation.
From an intellectual-property perspective,
United States patent law does not create a separate “cosmeceutical patent”
category. Formulations must satisfy the ordinary requirements of patentability,
including novelty, non-obviousness and utility. The comparative lesson is
therefore not that the United States grants special patents, but that
regulatory classification and patentability operate as separate legal
inquiries. The regulatory status of a product does not itself determine whether
the underlying technical invention is patentable.
7.2
European Union
The European Union regulates cosmetic
products principally under Regulation (EC) No 1223/2009. The framework combines
ingredient controls, safety assessment, responsible-person obligations and
rules concerning claims. The European Commission’s guidance emphasises that
cosmetic claims should be supported by adequate and verifiable evidence and
should not create an impression inconsistent with the available proof. This
provides a useful model for India because it shows that enhanced consumer
protection need not require every cosmeceutical to be treated as a
pharmaceutical drug.[14]
The EU model therefore supports a
proportionate approach: cosmetics can remain cosmetics, but the safety and
evidentiary obligations become more demanding as the risk and strength of the
claim increase. The key lesson for India is regulatory alignment rather than
transplantation of foreign law. Ingredient restrictions, safety assessment and
claim substantiation can be adapted to Indian conditions while retaining the
basic distinction between cosmetic and medicinal products.
7.3
Comparative Lessons for India
The comparison reveals three broad models.
The United States places strong weight on claims and intended use; the European
Union maintains a cosmetics framework with structured safety and claim
requirements; India relies on an older binary statutory architecture without an
express cosmeceutical category. India need not reproduce either foreign model
in full. Instead, it can combine their most useful features: claims-based
classification, proportionate substantiation, risk-based ingredient controls
and clearer institutional responsibility.
8. CRITICAL LEGAL ISSUES
8.1
Regulatory Classification Ambiguity
The central problem is the
appearance-versus-function distinction. Small differences in wording can change
the perceived legal character of a product, while consumers may understand the
claims in substantially the same way. This creates uncertainty for manufacturers
and regulators and can produce inconsistent enforcement. The absence of a
dedicated category also makes it difficult to prescribe intermediate safety and
evidence requirements.
8.2
Regulatory–IP Misalignment
The most significant structural problem is
the mismatch between market regulation and patent protection. If a product can
be marketed as a cosmetic without generating evidence comparable to that
required for a drug, an inventor may have little commercial incentive to incur
the cost of pharmaceutical-level evidence merely to satisfy a patent objection.
Yet a formulation patent may be challenged under sections 3(d), 3(e) or 2(ja)
when the claimed contribution is a new
combination of known actives. This can
encourage secrecy, rapid imitation and brand-based competition rather than
investment in disclosed technical innovation.
8.3
Consumer Information and Safety
Cosmeceuticals create an information
asymmetry because consumers may not know whether a statement is supported by a
laboratory test, a consumer study or a clinical investigation. The stronger the
implied physiological benefit, the greater the need for transparent
substantiation. A regulatory framework should also provide a mechanism for
collecting complaints and adverse-event information so that emerging safety
signals are not left entirely to general consumer remedies.
8.4
Misleading Terminology and Ingredient Representation
Terms that imply pharmaceutical quality or
clinical validation can be particularly problematic. The same is true of
ingredient-centred representations that mention sophisticated technologies or
biological materials without explaining concentration, function or the limits
of the evidence. The problem is not merely technical accuracy; a statement may
be literally true yet materially misleading in context. Consumer law should
therefore assess the overall impression created by the claim.
8.5
Regulatory Arbitrage
Differences between jurisdictions can also
encourage regulatory arbitrage. A manufacturer operating across markets may
encounter different ingredient restrictions, claim requirements and evidence
thresholds. If Indian regulation is substantially less demanding than major
export markets, products or claims may be tailored differently for India. Clear
and internationally compatible standards would reduce this divergence while
preserving regulatory space for domestic conditions.
9. PROPOSED REFORMS
9.1
Statutory Recognition and Three-Tier Classification
The DCA should recognise cosmeceuticals
expressly and establish a three-tier structure: (A) ordinary cosmetics making
basic cleansing, grooming or appearance claims; (B) cosmeceuticals making
therapeutic-adjacent or biologically active claims without claiming to
diagnose, cure or prevent disease; and (C) drugs making disease-related
therapeutic claims. The category should be determined primarily by intended use
and claims, supported where necessary by formulation and risk information.
A statutory definition should be deliberately
narrow. A possible formulation is: “Cosmeceutical” means a topical preparation
containing a biologically active ingredient and marketed for a specified
aesthetic or skin-function benefit beyond basic cleansing or grooming, but not
represented as diagnosing, curing, treating, mitigating or preventing disease.
The purpose is classification, not the creation of a new unregulated class.
9.2
Proportionate Safety and Claim Substantiation
Cosmeceuticals should be subject to a
proportionate evidence framework. Low-risk aesthetic claims may be supported by
appropriately designed consumer or laboratory studies; stronger biological
claims should require stronger evidence, including controlled clinical evidence
where the nature of the claim warrants it. The manufacturer should retain
substantiation material and make an evidence summary available to regulators
and, where appropriate, consumers.
Labels should distinguish between appearance
claims and physiological or therapeutic claims. Where a percentage improvement
is stated, the basis of measurement should be identified. Terms such as
“clinically proven”, “pharmaceutical grade” or “dermatologist approved” should
not be used unless the manufacturer can demonstrate what the statement means
and possesses evidence commensurate with the representation.
9.3
Patent Examination Reform
Patent law should not create a special
monopoly for cosmeceuticals, but examination guidance should explain how
ordinary patent standards apply to formulation inventions. Under section 3(e),
the focus should remain on whether the combination is a mere admixture or
produces a materially different property. Under section 3(d), the inquiry
should be tied to the claimed technical contribution rather than assuming that
every cosmetic innovation must establish a pharmaceutical therapeutic outcome.
Evidence of unexpected stability, compatibility, controlled delivery or
measurable cosmetic performance may be relevant where it genuinely demonstrates
the claimed technical effect.
The Indian Patent Office could publish
clearer examination examples dealing with combinations of known actives,
encapsulation technologies, delivery systems and formulation stability. Such
guidance would improve predictability without diluting the requirements of
novelty and inventive step.
9.4
Trademark and Advertising Controls
Trademark examination and advertising
enforcement should remain conceptually distinct, but they should communicate
with each other where a mark or associated representation implies a regulated
health benefit. Health-suggestive branding should not be treated as scientific
proof. Advertising rules should require manufacturers to possess substantiation
before making quantified efficacy, clinical or professional-endorsement claims.
9.5
Institutional Coordination and Adverse-Event Reporting
A dedicated expert mechanism within the
existing regulatory structure could issue classification guidance, maintain
claim-substantiation standards, coordinate with state authorities and review
safety signals. Rather than creating a wholly separate regulator, India could
use a specialised expert committee supported by CDSCO and coordinated with
state drug authorities. A simplified reporting mechanism for adverse reactions
and serious consumer complaints would improve post-market surveillance.
9.6
Ingredient and Concentration Transparency
For ingredients capable of producing
significant biological effects, greater concentration transparency should be
considered, subject to legitimate confidential-information concerns. Consumers
should be able to compare meaningful information about active ingredients and
understand the intended use and limitations of the product. Transparency should
be balanced against the need to protect genuinely confidential manufacturing
know-how.
9.7
International Harmonisation
India should draw on the EU and US approaches
while avoiding direct transplantation. Internationally compatible ingredient
restrictions, claim-substantiation principles and safety assessment terminology
would reduce compliance costs for exporters and limit regulatory arbitrage. The
ASEAN experience also demonstrates the value of regional harmonisation while
allowing domestic regulatory choices.[15]
9.8
Institutional Fragmentation and Regulatory Predictability
The classification problem is closely
connected with institutional fragmentation. The central regulator and state
authorities may perform different functions, while consumer-protection
institutions address misleading representations from a different statutory
perspective. For a hybrid product, this can produce overlapping but incomplete
forms of supervision. A manufacturer may understand a product to be compliant
because it satisfies the requirements associated with cosmetics, while a claim
may nevertheless attract scrutiny under consumer-protection principles.
Conversely, a consumer may challenge an advertisement without possessing the
technical information needed to determine whether the underlying efficacy
representation is justified.
Predictability is therefore a substantive
regulatory value. Businesses require sufficiently clear rules to determine the
evidence that must be generated before launch, and consumers require
sufficiently clear information to distinguish a cosmetic benefit from a
therapeutic claim. The answer is not necessarily a single regulator for every
aspect of the product. A more realistic approach is coordinated administration:
a central technical mechanism can establish classification and substantiation
guidance, while state authorities continue ordinary enforcement and consumer
institutions retain their statutory jurisdiction. Clear referral and
information-sharing procedures would reduce duplication and inconsistent
outcomes.
The proposed approach should also recognise
the diversity of cosmeceutical products. A low-risk moisturising product
containing a biologically active botanical should not automatically face the
same evidentiary burden as a formulation claiming to modify inflammatory
pathways or deliver a high-potency active. Regulation should therefore be
risk-based. Classification should consider the nature of the active ingredient,
concentration, route of application, intended user population and the
seriousness of the claim. This would permit regulatory resources to be
concentrated on products presenting greater potential risk while avoiding
unnecessary burdens on ordinary personal-care innovation.
9.9
The Need for Regulatory–IP Alignment
Intellectual-property policy and product
regulation should be designed as complementary rather than isolated systems.
Patent law rewards disclosure of technical innovation by granting time-limited
exclusivity, whereas product regulation protects consumers by controlling
safety and representations. If regulatory requirements are minimal but patent
standards are perceived as disproportionately demanding, the system may
encourage firms to compete through branding, secrecy and marketing rather than
through disclosed technical research. That outcome is undesirable where the
underlying objective is to promote safe and evidence-based innovation.
Alignment does not mean that regulatory
approval should guarantee a patent, or that patentability should determine
whether a product can be sold. The two inquiries serve different purposes.
Alignment means that the evidence demanded by each system should be
intelligible and proportionate to the claimed contribution. For example, where
a cosmeceutical applicant demonstrates a new delivery system producing an
objectively measurable improvement in stability or controlled release, patent
examination should consider that technical evidence under the ordinary
statutory tests. The regulatory system can separately determine whether the
associated consumer claim is sufficiently substantiated. This separation
preserves the integrity of both regimes while avoiding contradictory
incentives.
A clearer framework would also improve
investment decisions. Companies deciding whether to patent a formulation must
assess disclosure costs, prosecution risk and the likelihood of imitation. If
examination practice is predictable and the evidentiary pathway is transparent,
innovators can make that decision on commercial and technical grounds rather
than regulatory uncertainty. The same predictability benefits smaller Indian
enterprises, which may lack the resources of multinational companies to maintain
multiple formulations, labels and evidence packages for different markets.
9.10
Implementation Roadmap
Reform can be implemented incrementally
rather than through an entirely new regulatory statute. The first stage should
be definitional. The DCA and subordinate rules should identify the
characteristics of a cosmeceutical and establish the boundary between cosmetic,
cosmeceutical and drug claims. The second stage should establish claim
categories and minimum substantiation requirements. This could begin with
guidance and model claim language, followed by binding rules after consultation
with industry, regulators, dermatologists, toxicologists and consumer
organisations.
The third stage should address intellectual
property. The Indian Patent Office should publish examination examples dealing
specifically with formulation combinations, encapsulation, delivery
technologies and evidence of unexpected technical effects. These examples
should clarify how sections 2(ja), 3(d) and 3(e) interact without creating a
separate lower patentability standard. The objective is greater consistency and
transparency, not automatic grant of patents to products labelled as
cosmeceuticals.
The fourth stage should strengthen
post-market oversight. Manufacturers should maintain records of substantiation
and complaints, and a proportionate reporting system should identify serious or
recurring adverse events. Regulators should periodically review claims and
ingredient restrictions as scientific knowledge develops. Finally, India should
use international regulatory experience as a reference point for periodic
review, particularly in relation to prohibited or restricted ingredients,
safety assessment and claims.
Implementation should be accompanied by
transitional arrangements. Existing products should receive a reasonable period
in which to review classification, labels and substantiation. New products
should comply from the commencement date. Regulatory guidance should be
publicly accessible and written in sufficiently clear terms to reduce
dependence on informal advice. An effective framework should also include an
appeal or review mechanism for disputed classification decisions, thereby
improving procedural fairness and reducing unnecessary litigation.
The overall objective is a proportionate
regulatory architecture rather than maximal regulation. The Indian market
requires room for formulation innovation, small and medium enterprises and
consumer choice, but those interests should operate within a framework that
prevents unsupported therapeutic impressions. The most sustainable model is
consequently one in which regulatory obligations increase with the strength of
the claim and the potential risk of the product, while intellectual-property
rights remain governed by ordinary patent and trademark principles supported by
clearer sector-specific guidance.
10. CONCLUSION
Cosmeceuticals expose a structural weakness
in Indian regulatory design: a product category that is commercially and
technologically significant is being accommodated within a binary legal
framework that was not drafted specifically for hybrid products. The absence of
an express category affects classification, safety requirements, advertising,
intellectual-property strategy and enforcement. The resulting uncertainty is
not adequately solved by treating all cosmeceuticals as drugs or all of them as
ordinary cosmetics.
The patent dimension reinforces the problem.
Sections 2(ja), 3(d) and 3(e) provide legitimate safeguards against obvious,
repetitive or weakly differentiated inventions, but their application to modern
formulation technologies should remain connected to the actual technical
contribution claimed. The objective should be neither automatic patentability
nor pharmaceutical-level evidence for every cosmetic innovation. It should be a
predictable application of ordinary patent principles to the particular technical
problem and result demonstrated by the applicant.
Consumer protection requires a similar
principle of proportionality. Claims should be matched to evidence. The
stronger the implied therapeutic or physiological benefit, the stronger the
substantiation should be. Trademark registration should not be confused with
scientific validation, and advertising should be assessed according to the
overall impression conveyed to consumers. Coordinated enforcement is essential
because a single product may simultaneously implicate cosmetics regulation,
intellectual property and consumer law.
The most appropriate reform is therefore an
integrated framework recognising three levels cosmetics, cosmeceuticals and
drugs while applying proportionate safety and evidence requirements. A
dedicated statutory definition, clearer patent examination guidance, stronger
claim-substantiation rules, coordinated enforcement and improved post-market
reporting would provide greater certainty without imposing the full burden of
pharmaceutical regulation on every advanced skincare product. Such a framework
would better balance innovation, competition, consumer choice and public health
in India’s growing cosmeceutical sector.
BIBLIOGRAPHY
1. Statutes
and Regulations
2.
The Drugs
and Cosmetics Act, 1940, No. 23 of 1940 (India), as amended.
3.
The Drugs
and Cosmetics Rules, 1945, as amended.
4.
The
Patents Act, 1970, No. 39 of 1970 (India), as amended.
5.
The Trade
Marks Act, 1999, No. 47 of 1999 (India), as amended.
6.
The
Consumer Protection Act, 2019, No. 35 of 2019 (India).
7.
Regulation
(EC) No. 1223/2009 on Cosmetic Products (European Union).
Cases
1.
Novartis
AG v Union of India & Others, (2013) 6 SCC 1.
2.
Colgate-Palmolive
Co v Hindustan Lever Ltd, 2008 (12) SCC 305.
Government,
Regulatory and Industry Sources
1.
Central
Drugs Standard Control Organization (CDSCO), Guidelines on Cosmetics (2017).
2.
Indian
Patent Office, Patent Prosecution Guidelines: Cosmetic and Pharmaceutical
Formulations (2020).
3.
Ministry
of Commerce and Industry, National Intellectual Property Policy 2016 and
Implementation Status (2018).
4.
European
Commission, Cosmetics Regulation Guidance: Claim Substantiation and Safety
Assessment (2019).
5.
US Food
and Drug Administration, Guidance for Industry: Cosmetics vs Drugs—Claims
Classification (2017).
6.
ASEAN
Secretariat, ASEAN Harmonized Cosmetics Regulatory Framework (2018).
7.
Grand
View Research, Global Cosmeceuticals Market Report 2023–2030 (2023).
8.
Indian
Society of Cosmetic Chemists, Cosmeceutical Industry Survey: Patent, Trademark
and Trade Secret Protection Practices (2019).
[1] The Consumer Protection Act, 2019,
s 2(47).
[2] Grand View
Research, Global Cosmeceuticals Market Report 2023–2030 (2023).
[3] The Drugs and Cosmetics Act, 1940
[4] The Patents Act, 1970, ss 2(1)(j),
2(ja), 3(d) and 3(e).
[5] The Drugs and Cosmetics Act, 1940
[6] The Drugs and Cosmetics Rules,
1945, as amended.
[7] The Patents Act, 1970, s 3(e).
[8]Indian Patent
Office, Patent Prosecution Guidelines: Cosmetic and Pharmaceutical Formulations
(2020).
[9] Novartis AG v Union of India &
Others, (2013) 6 SCC 1.
[10] The Trade Marks
Act, 1999, s 9.
[11] The Consumer Protection Act, 2019
[12] Colgate-Palmolive Co v Hindustan
Lever Ltd, 2008 (12) SCC 305.
[13] Indian Society of Cosmetic
Chemists, Cosmeceutical Industry Survey: Patent, Trademark and Trade Secret
Protection Practices (2019).
[14] European
Commission, Cosmetics Regulation Guidance: Claim Substantiation and Safety
Assessment (2019).
[15] ASEAN
Secretariat, ASEAN Harmonized Cosmetics Regulatory Framework (2018).
How to Cite This Article
A.AARTHI, A.BENTLEY BENEDICT MARAN, INTELLECTUAL PROPERTY RIGHTS AND REGULATORY GAPS IN THE INDIAN COSMECEUTICAL INDUSTRY., White Black Legal – International Law Journal, ISSN: 2581-8503, Vol. 4, Issue 1, September 2026, pp. 688-708, DOI Link: https://www.doi-ds.org/doilink/09.2026-37711597/INTELLECTUAL PROPERTY RIGHTS AND REGULATORY GAPS I. Available at: https://www.whiteblacklegal.co.in/public/details/intellectual-property-rights-and-regulatory-gaps-in-the-indian-cosmeceutical-industry
Author & Publication Record
Authors: A.AARTHI
& A.BENTLEY BENEDICT MARAN
Registration ID: 107092 | Published Paper ID: WBL7092 & WBL7093
Year: Sep- 2026 | Volume: 4 | Issue: 1
Approved ISSN: 2581-8503 | Country: Delhi, India
Page No.: 688-708
Full Text Preview
Open in New Tab
Copied